The current standard of care for patients with CML-CP is therapy with BCR::ABL1-targeted TKIs with the potential for hematopoietic cell transplant (HCT) for eligible patients who no longer respond to these agents or whose disease progresses to a more advanced stage (Table 1) (2, 3). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.